Oslo, Norway 5 March 2025 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing powerful circular RNA technology for next generation nucleic acid medicine, today announces that CEO Dr. Erik Digman Wiklund and CSO Dr. Victor Levitsky are presenting updated data demonstrating the significant advantages of Circio’s circular RNA circVec platform compared to current mRNA-based vector technology. The data further strengthens the in vitro and in vivo validation of Circio’s platform. The presentations are being delivered at two major biopharma industry conferences in Basel, Switzerland, and Stockholm, Sweden.
The presentations detail the advantages and potential of the circVec 3.0 generation to improve on current mRNA-based technology for a range of therapeutic applications. In vivo expression data has shown an estimated circRNA half-life of over 600 hours vs. under 10 hours for linear mRNA, which translates to over 70 times prolonged RNA durability and 15 times enhanced protein expression.
Novel systemic LNP-delivery data demonstrates robust and durable circVec expression in spleen, far outperforming equivalent mRNA-vectors. This important finding has the potential to open up attractive therapeutic opportunities for the circVec technology in several areas, such as cell therapy. Further experimental work is currently ongoing to validate and characterize these observations.
“The recent results showing efficient and specific circVec delivery to spleen are very promising and hints at novel opportunities for our circular RNA platform in cell and immune therapies,” said Dr. Victor Levitsky, CSO of Circio. “A broad set of experiments to further investigate this observation, as well as in vivo testing of the novel circVec 3.0 generation, will read out over the next 6-12 weeks. The performance of circVec 3.0-AAV constructs is of particular interest, which we believe has the potential to transform current gold-standard AAV gene therapy and generate substantial partnering interest.”
See below for titles and presentation materials:
RNA Leaders Europe Congress
Title: Deploying circular RNA expression to boost gene therapy – AAV and beyond
Time & place: 5 March 2025, Basel, SwitzerlandPresenter: Dr. Erik Digman Wiklund, CEO
Biologics World Nordics 2025
Title: CircVec – A Novel Payload Expression Platform Based on Circular RNA Biogenesis: Features and Opportunities
Time & place: 5 March 2025, Stockholm, Sweden
Presenter: Dr. Victor Levitsky, CSO
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com
Neil Hunter – Hunter PR
Phone:+44 7821 255568
Email: neiljameshunter@gmail.com
About Circio
Building next generation RNA technology for nucleic acid medicine
Circio Holding ASA is a biotechnology company developing powerful circular RNA vector expression technology for next generation nucleic acid medicine.
Circio has established a unique circular RNA (circRNA) vector expression platform for novel DNA, RNA and viral therapeutics. The proprietary circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA inside cells, which can be deployed in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. The circVec platform has demonstrated up to 15-fold enhanced and more significantly more durable protein expression vs. classic mRNA vector systems and has the potential to become a new gold-standard platform technology for nucleic acid and viral therapeutics in the future. The circRNA R&D activities are being conducted by the wholly owned subsidiary Circio AB based at the Karolinska Institute in Stockholm, Sweden.
In addition, Circio is developing a pan-RAS cancer vaccine, TG01, targeting KRAS driver mutations. TG01 is currently being tested in two clinical trials: RAS-mutated pancreatic and lung cancer in the USA and multiple myeloma in Norway. These studies are being run through academic and industry collaborative networks, supported by prestigious research grants from Innovation Norway and the Norwegian Research Council, creating read-outs and future optionality for the program at low cost to Circio.